Verismo Therapeutics has dosed the first patient in its Phase 1 CELESTIAL-301 trial of SynKIR-310, a novel CAR T-cell therapy, at the Colorado Blood Cancer Institute.
Verismo Therapeutics has initiated the CELESTIAL-301 Phase 1 trial to evaluate SynKIR™-310 in patients with relapsed/refractory B-cell Non-Hodgkin Lymphomas.
The FDA has cleared the IND application for Verismo Therapeutics' SynKIR-310, a novel CAR-T therapy, for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.